HOME > COMMENTARY
COMMENTARY
-
Hardships and Successes of Diversified Entrants Lead to Question: Will Pharmaceuticals Continue to Be a Growth Sector?
March 5, 2014
-
Revised JCS Guidelines Clarify Role of Novel Oral Anticoagulants in Patients with Atrial Fibrillation
February 12, 2014
-
Will JPWA’s Move to Integrate Tax Display Method Dispel Medical Institutions’ Misconception?
January 31, 2014
-
FY2014 May Be Year 1 of New Reform Era; Drug Makers Need to “Turn Calamity into Good Fortune”
January 7, 2014
-
First SGLT-2 Inhibitor Set to Debut Next April; Curtain Rising on “Unprecedentedly Competitive” Market
December 18, 2013
-
Bearing “Edo” in Its Name, Japan-Originated Edoxaban Set to Challenge Rival Anticoagulants in World Market
December 6, 2013
-
MHLW Shocks Generic Drug Industry by Proposing “50% Rule,” Expansion of Uniform Pricing
November 19, 2013
-
Range of Drugs Eligible for Premium for New Drug Development May Be Reviewed; Industry Needs to Dispel Suspicions
November 13, 2013
-
Interim Report of Diovan Committee Raises Further Questions
October 15, 2013
-
Remicade Biosimilar Debut Awaited in FY2014; Good Opportunity to Revisit Healthcare Finance?
October 4, 2013
-
Comprehensive Review of Package Inserts to Begin with Effort to Identify Inconsistencies Between Inserts for Similar Drugs
August 27, 2013
-
Transparency Guidelines Go Live, Will It Help Pharmas Win Public Trust?
August 2, 2013
-
Overseas Outlook Will Be Essential to Survival and Progress of Domestic CROs
June 24, 2013
-
PMDA’s Seriousness About Becoming a Leading Global Regulatory Authority to Be Tested
May 30, 2013
-
Beyond Risk Management: RMPs Provide Opportunity for Post-Marketing Drug Development and Product Differentiation
May 8, 2013
-
Iressa Cases Signal Risks Hiding in Daily Clinical Practices
April 22, 2013
-
Will Drugs that Fight Cancer Stem Cells Succeed? Domestic Clinical Trial by DSP on the Horizon
March 15, 2013
-
Gov’t, Industry to Support Developing Countries through Development of Drugs for Infectious Diseases; Hoping to Secure Future Business Opportunities as Well
February 27, 2013
-
What Next for a “Mature” ICH? What More Can Be Done Beyond Regulatory Harmonization?
January 22, 2013
-
Hot Products in 2013: New Drugs Likely to Jolt RA Treatment, Anticoagulant Markets
January 8, 2013
ページ
The advance of cell therapy is one of the most exciting innovations in medical treatment in recent years. These drugs offer potential curative treatments for severe or previously fatal diseases. In this article, I will explain features and challenges in…
The Liberal Democratic Party (LDP) will wrap up its discussions on the FY2023 tax reform plan within a few days. Some provisions of the R&D tax credit system, which allow drug makers to deduct a portion of R&D expenses from…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…